Literature DB >> 21908146

Mesenchymal stem cells attenuate angiotensin II-induced aortic aneurysm growth in apolipoprotein E-deficient mice.

Ryotaro Hashizume1, Aika Yamawaki-Ogata, Yuichi Ueda, William R Wagner, Yuji Narita.   

Abstract

OBJECTIVE: Aortic aneurysm (AA) is associated with loss of elastin and structural integrity, accompanied by increased matrix metalloproteinase (MMP) expression. These processes are supported by inflammatory macrophages, with mediators such as tumor necrosis factor-α (TNF-α). Mesenchymal stem cells (MSCs) contribute to aortic remodeling. Therefore, to clarify whether MSCs might be useful for AA cell therapy, we examined the effect of MSCs on vascular smooth muscle cells (SMCs) and macrophages in vitro, on aortic tissue ex vivo, and on aorta in vivo.
METHODS: Murine macrophages and SMCs were cultured, with or without bone marrow-derived murine MSCs, for 96 hours in vitro. Gene expression of MMPs and TNF-α from macrophages and that of elastin from SMCs were measured. The murine aortic tissues were cultured with or without MSCs for up to 14 days, followed by measurement of MMP enzyme activity and elastin content. The in vivo aneurysm model used apolipoprotein E-deficient (apoE(-/-)) male mice receiving angiotensin II (Ang II) infusion for 28 days. MSCs were implanted by laparotomy to the abdominal aortic adventitial surface from the superior mesenteric artery origin to the left renal artery. Age-matched apoE(-/-) mice with or without Ang II infusion were used for control groups. At the end point, aortic diameter, elastin content, MMPs' activity, and cytokines expressed, including interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), TNF-α, insulin-like growth factor-1 (IGF-1), and tissue inhibitor of metalloproteinases-1 (TIMP-1) were quantified.
RESULTS: MSCs suppressed MMP-2 with or without MSCs (2.59 vs 3.94, P < .05), MMP-9 (5.83 vs 9.70, P < .05), and TNF-α (2.79 vs 3.38, P < .05) expression in macrophages, and promoted elastin expression in SMCs (19.35 vs 3.23, P < .05) in vitro. MSCs also decreased active MMP-2 activity (0.310 vs 0.0609 U/μL, P < .05) and preserved elastin content (68.05 vs 40.29 μg/mg, P < .05) ex vivo. AA development was site-specifically inhibited (0.73 vs 1.04 mm aortic diameter, P < .05) and elastin content was preserved (46.9 vs 25.6 μg/mg, P < .05) at 4 weeks. Downregulation of MMPs and IL-6, MCP-1, and TNF-α, and upregulation of IGF-1 and TIMP-1 were demonstrated with MSC implantation in vivo.
CONCLUSIONS: MSC implantation inhibits Ang II-induced AA development in apoE(-/-) mice through elastin preservation in the aortic wall and is associated with attenuated levels of MMPs and inflammatory cytokines.
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908146     DOI: 10.1016/j.jvs.2011.06.109

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  28 in total

1.  Human Adipose-Derived Stem Cells Suppress Elastase-Induced Murine Abdominal Aortic Inflammation and Aneurysm Expansion Through Paracrine Factors.

Authors:  Jie Xie; Thomas J Jones; Dongni Feng; Todd G Cook; Andrea A Jester; Ru Yi; Yameena T Jawed; Clifford Babbey; Keith L March; Michael P Murphy
Journal:  Cell Transplant       Date:  2016-07-18       Impact factor: 4.064

2.  Composition of intraperitoneally implanted electrospun conduits modulates cellular elastic matrix generation.

Authors:  Chris A Bashur; Anand Ramamurthi
Journal:  Acta Biomater       Date:  2013-09-07       Impact factor: 8.947

Review 3.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

Review 4.  Mesenchymal stem cells for treatment of aortic aneurysms.

Authors:  Aika Yamawaki-Ogata; Ryotaro Hashizume; Xian-Ming Fu; Akihiko Usui; Yuji Narita
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

5.  Mesenchymal Stem Cells Attenuate NADPH Oxidase-Dependent High Mobility Group Box 1 Production and Inhibit Abdominal Aortic Aneurysms.

Authors:  Ashish K Sharma; Morgan D Salmon; Guanyi Lu; Gang Su; Nicolas H Pope; Joseph R Smith; Mark L Weiss; Gilbert R Upchurch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-17       Impact factor: 8.311

6.  Human mesenchymal stromal cell-derived extracellular vesicles attenuate aortic aneurysm formation and macrophage activation via microRNA-147.

Authors:  Michael Spinosa; Guanyi Lu; Gang Su; Sai Vineela Bontha; Ricardo Gehrau; Morgan D Salmon; Joseph R Smith; Mark L Weiss; Valeria R Mas; Gilbert R Upchurch; Ashish K Sharma
Journal:  FASEB J       Date:  2018-05-29       Impact factor: 5.191

7.  The effect of polymer degradation time on functional outcomes of temporary elastic patch support in ischemic cardiomyopathy.

Authors:  Ryotaro Hashizume; Yi Hong; Keisuke Takanari; Kazuro L Fujimoto; Kimimasa Tobita; William R Wagner
Journal:  Biomaterials       Date:  2013-07-01       Impact factor: 12.479

8.  Perspectives on stem cell-based elastic matrix regenerative therapies for abdominal aortic aneurysms.

Authors:  Chris A Bashur; Raj R Rao; Anand Ramamurthi
Journal:  Stem Cells Transl Med       Date:  2013-05-15       Impact factor: 6.940

9.  Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment.

Authors:  Ashish K Sharma; Guanyi Lu; Andrea Jester; William F Johnston; Yunge Zhao; Vanessa A Hajzus; M Reza Saadatzadeh; Gang Su; Castigliano M Bhamidipati; Gaurav S Mehta; Irving L Kron; Victor E Laubach; Michael P Murphy; Gorav Ailawadi; Gilbert R Upchurch
Journal:  Circulation       Date:  2012-09-11       Impact factor: 29.690

10.  Rat mesenchymal stem cell secretome promotes elastogenesis and facilitates recovery from simulated childbirth injury.

Authors:  Charuspong Dissaranan; Michelle A Cruz; Matthew J Kiedrowski; Brian M Balog; Bradley C Gill; Marc S Penn; Howard B Goldman; Margot S Damaser
Journal:  Cell Transplant       Date:  2013-07-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.